News Releases

- Reprioritized resources to reduce costs and enhance focus on Nana-val’s development program in relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL) - - On track to report data...

Company implementing 42% reduction in force and resizing its Board of Directors to six seats from ten SAN DIEGO, November 6, 2024 – Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage...

SAN DIEGO, September 3, 2024 – Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that...

- Reported combined Stage 1 and Stage 2 results from the relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL) cohort of the Phase 2 NAVAL-1 trial demonstrating Nana-val’s...

- New combined Stage 1 and Stage 2 results from the relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL) cohort of the Phase 2 NAVAL-1 trial further demonstrate Nana-val’s...

San Diego, May 17, 2024 – Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact...

San Diego, May 14, 2024 – Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact...

Presented positive topline Nana-val results from Stage 1 of the pivotal Phase 2 NAVAL-1 trial in patients with relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) peripheral T-cell...

SAN DIEGO, May 7, 2024 – Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact...

San Diego, April 15, 2024 – Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact...